[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584328":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Sickle cell disease patients at rest since at least 1 year",null,"Patient at steady state since at least 1 year",{"label":13,"type":10,"description":14,"interventionNames":10},"Sickle cell disease patients at rest","Patient at steady state (without crises)",{"label":16,"type":10,"description":17,"interventionNames":10},"Vaso-occlusive crisis","Sickle cell disease patients during vaso-occlusive crisis",{"label":19,"type":10,"description":20,"interventionNames":10},"Acute chest syndrome","Sickle cell disease patients during acute chest syndrome",[22],{"name":23,"affiliation":5,"role":24},"Pierre COUGOUL, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","0531156265","33","cougoul.pierre@iuct-oncopole.fr",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":36,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU de Toulouse","RECRUITING","Toulouse","France","31059","FR",{"type":40,"coordinates":41},"Point",[42,43],1.44367,43.60426,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584328","phenotypic-and-transcriptomic-description-of-megakaryocytes-in-sickle-cell-patient-100584328",false,"NCT06887907","Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient","MEGADREP","Inclusion Criteria:\n\n* Sickle cell disease SS or S-béta° thalassemia\n* Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome\n* Age \\> 18 years old\n\nExclusion Criteria:\n\n* Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)\n* Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23\n* Anti-platelets agents\n* Red blood cell exchange or transfusion \\\u003C 3 months","ALL","18 Years",{"count":59,"type":60},40,"ESTIMATED","OBSERVATIONAL","Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.",[64],"Sickle Cell Disease (SCD)",[66,67],"Megakaryocyte","Sickle Cell Disease","2025-03-14",{"date":70,"type":71},"2025-03-20","ACTUAL",{"date":73,"type":71},"2025-03-13",{"date":75,"type":60},"2028-04-01",{"name":5,"class":6},1]